McKesson in $190M False Claims Act settlement
McKesson Corp, a large U.S. drug wholesaler, has agreed to pay more than $190 million to settle claims that it violated the federal False Claims Act by reporting inflated pricing information for many prescription drugs, causing Medicaid to overpay for those drugs. The settlement was announced Thursday by U.S. Attorney Paul Fishman in New Jersey. McKesson did not admit liability in agreeing to settle. According to the government, McKesson reported inflated pricing data to First DataBank, a publisher of drug prices that most state Medicaid programs use to set payment rates for pharmaceutical products. Fishman said state governments may negotiate separately with McKesson to resolve claims based on their individual shares of the Medicaid overpayments.
- CFO Exchange: Smartphones Poised to Disrupt Healthcare, Says Topol
- How Digital Strategy Shapes Patient Engagement at Boston Children's Hospital
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- CNO on Hospital Redesign: 'You Can't Over-Communicate'
- Carondelet to Pay $35M to Settle Fraud Allegations
- Some Cancer Hospitals' Quality Data Will Soon Be Public
- Consumerism Drives Healthcare Branding, Rebranding Efforts
- PA Ranks See 'Phenomenal Growth,' Lack of Diversity
- CA Powers Up $80M HIE to 'Create Value in the Data'
- 3 Traits Personality Assessments Can't Reveal